Contributor Page
Smart & Biggar
 
Email  |  Website  |  Articles
Contact Details
Tel: +1 416 5935514
Fax: +1 416 5911690
1100-150 York Street
Toronto
ON M5H 3S5
Canada
By Katie Lee
The Federal Court had previously allowed a concurrent trial on common invalidity issues in actions under the Patented Medicines (Notice of Compliance) Regulations (PMNOC Regulations)...
By Eleanor Wilson
On November 7, 2019, Prothonotary Tabib dismissed Pharmascience's motion for an order directing a preliminary determination of a question of law in the context of a patent infringement action...
By Chen Li (Articling Student), Alice Tseng
On October 28, 2019, the Ontario Ministry of Health and Long-Term Care (the Ministry) published proposed changes to Regulations made under the Ontario Drug Benefit Act (ODBA)...
By Brandon Heard
As previously reported, the Federal Court granted Teva's claim for compensation under section 8 of the Patented Medicines (Notice of Compliance) Regulations relating to Teva's bortezomib product...
By Urszula Wojtyra
As more biosimilars continue to be approved across the world, it is helpful to compare the applicable regimes across major jurisdictions. We have collaborated with Brian Coggio of Fish & Richardson...
By Abigail Smith, Daphne Lainson, Nancy Pei
Yesterday, the Patented Medicines Prices Review Board ("PMPRB") released draft new Guidelines for consultation, together with a backgrounder (see also news release here).
By Abigail Smith
On October 29, 2019, the Federal Court issued its final decision under the pre-amended Patented Medicines (Notice of Compliance) Regulations: Janssen Inc v Apotex Inc, 2019 FC 1355.
By Mark Biernacki, Tierney Deluzio
In IP litigation, expert testimony is common and important. Experts may provide the court with a scientific primer in highly complex cases. In patent litigation,...
By François Guay, Guillaume Lavoie Ste-Marie, Olivier Jean-Lévesque
On November 15, 2019, the Federal Court issued an Order compelling Canada's primary Internet service providers ("ISPs") to block their subscribers ...
By Urszula Wojtyra
The following provides an overview of the many developments regarding biosimilars in Canada (approvals, pending submissions, regulatory, litigation and market access) that have taken place since our last update in June 2018.
By Katie Lee, Urszula Wojtyra
September 21, 2019 was the second anniversary of the coming into force of the amended Patented Medicines (Notice of Compliance) Regulations heralding significant changes to the landscape for pharmaceutical companies in Canada.
By Brandon Heard, Nancy Pei, Daphne Lainson
September 21, 2019 marked the second anniversary of the certificate of supplementary protection regime in Canada.
By Eleanor Wilson, Daphne Lainson, Nancy Pei
They argue that the Impugned Amendments impermissibly expand the PMPRB's statutory mandate and jurisdiction, which the Governor in Council does not have authority to do by way of regulation.
By David Schwartz
Canada signed the PLT on May 21, 2001, and ratified the treaty on July 30, 2019.
By Nora Labbancz
Most entrepreneurs have a general understanding that trademarks are good for business.